CoraLite® Plus 488-conjugated HER2/ErbB2 Monoclonal antibody
HER2/ErbB2 Monoclonal Antibody for IF-P
Host / Isotype
Mouse / IgG2b
Reactivity
human
Applications
IF-P
Conjugate
CoraLite® Plus 488 Fluorescent Dye
CloneNo.
1B12A7
Cat no : CL488-60311
Synonyms
Validation Data Gallery
Tested Applications
| Positive IF-P detected in | human breast cancer tissue |
Recommended dilution
| Application | Dilution |
|---|---|
| Immunofluorescence (IF)-P | IF-P : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
CL488-60311 targets HER2/ErbB2 in IF-P applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Mouse / IgG2b |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | HER2/ErbB2 fusion protein Ag16463 相同性解析による交差性が予測される生物種 |
| Full Name | v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
| Calculated molecular weight | 1255 aa, 138 kDa |
| GenBank accession number | BC156755 |
| Gene symbol | HER2/ErbB2 |
| Gene ID (NCBI) | 2064 |
| RRID | AB_2883140 |
| Conjugate | CoraLite® Plus 488 Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 493 nm / 522 nm |
| Form | Liquid |
| Purification Method | Protein A purification |
| Storage Buffer | PBS with 50% Glycerol, 0.05% Proclin300, 0.5% BSA, pH 7.3. |
| Storage Conditions | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
HER2, also known as ErbB2 and Neu, is a 185-kDa transmembrane glycoprotein that is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Amplification and/or overexpression of HER2 have been reported in numerous cancers, including breast and ovarian tumors. HER2 is a therapeutic target for the treatment of breast cancer and other carcinomas.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for CL Plus 488 HER2/ErbB2 antibody CL488-60311 | Download protocol |
| FC protocol for CL Plus 488 HER2/ErbB2 antibody CL488-60311 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
